AU Patent

AU2009228616B2 — Use of a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-Hodgkin' s lymphomas

Assigned to Roche Glycart AG · Expires 2014-07-24 · 12y expired

What this patent protects

The present invention is directed to the use an type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC) for the manufacture of a medicament for the treatment of cancer, especially of CD20 expressing cancers in combination with one ore more chemot…

USPTO Abstract

The present invention is directed to the use an type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC) for the manufacture of a medicament for the treatment of cancer, especially of CD20 expressing cancers in combination with one ore more chemotherapeutic agents selected from the group consisting of cyclophosphamide, vincristine and doxorubicine.

Drugs covered by this patent

Patent Metadata

Patent number
AU2009228616B2
Jurisdiction
AU
Classification
—
Expires
2014-07-24
Drug substance claim
No
Drug product claim
No
Assignee
Roche Glycart AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.